Large-scale study of blood markers in equine atypical myopathy reveals subclinical poisoning and advances in diagnostic and prognostic criteria.

The research involves a thorough investigation of blood markers in horses suffering from atypical myopathy (AM), a severe muscle breakdown syndrome, to create a more accurate diagnosis and prognosis. The study discovered the existence of asymptomatic AM cases amongst horses grazing together.

Overview of the Research

• This study was instigated to improve upon diagnostic and prognostic criteria for equine atypical myopathy (AM), a severe muscle breakdown condition in horses, primarily due to the presence of toxic compounds like hypoglycin A (HGA) and methylenecyclopropylglycine protoxins.
• Blood samples from 263 horses—95 AM cases, 73 from horses grazing alongside those with AM (referred to as cograzers), 19 colic cases, and 76 control horses—were scrutinized for the presence of HGA, its toxic metabolite, and an acylcarnitines profile.

Research Findings

• The horses afflicted with the disease exhibited changes in acylcarnitines, important biological markers often used in diagnostics. These changes were crucial in distinguishing them from control cases and colic horses.
• Regression analysis, a powerful statistical technique, was used to identify distinct acylcarnitine profiles among the four groups of horses. Horses grazing with the afflicted ones, though seemingly healthy, revealed intermediate alterations to their blood markers—indicative of potential AM risk.
• The study also revealed age and being a gelding (a neutered male horse) as protective factors, decreasing the likelihood of developing AM.

Importance of Acylcarnitines Profiling in Diagnosis and Prognosis

• Acylcarnitines profiling was shown to be valuable for predicting survival in AM cases. The unique profile also helped in differentiating between AM and other conditions, such as colic.
• Specifically, isovaleryl-/2-methylbutyrylcarnitine, also known as C5 acylcarnitine, was recognized as a promising diagnostic and prognostic marker in AM cases.

Discovery of Subclinical AM Cases

• Subtle changes in the blood markers of apparently healthy cograzers suggest the previously unknown presence of subclinical AM—cases where AM is present but not overtly symptomatic.
• This discovery could have significant implications for preventing AM by identifying it early in seemingly healthy horses.